Annovis wins US patent for Buntanetap in brain infection injuries

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Annovis secured U.S. Patent No. 12,582,632 B2 covering the prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap or related compounds. The patent, the company says, includes claims for preventive use in healthy individuals at risk of exposure and for reversal of neurological damage in affected patients, and protection extends through 2044.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE